← Back to Search

Unknown

BT-11 880 mg for Crohn's Disease

Phase 2
Waitlist Available
Research Sponsored by Landos Biopharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects aged 18 to 75 years with a diagnosis of CD for at least 3 months;
Moderately to severely active CD as defined by: a CDAI score of 220 450, and an SES-CD scored ≥ 6 ( ≥ 4 for isolated ileitis) (centrally read);
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This study is evaluating whether a drug called BT-11 can help people with Crohn's disease.

Eligible Conditions
  • Crohn's Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Remission Rate
Secondary outcome measures
Clinical response
Endoscopic Response
Endoscopic remission
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BT-11 880 mgExperimental Treatment1 Intervention
Oral once daily tablet
Group II: PlaceboPlacebo Group1 Intervention
Oral once daily tablet

Find a Location

Who is running the clinical trial?

Landos Biopharma Inc.Lead Sponsor
8 Previous Clinical Trials
499 Total Patients Enrolled
NImmune BiopharmaLead Sponsor
5 Previous Clinical Trials
324 Total Patients Enrolled
Jyoti ChauhanStudy DirectorLandos Biopharma Inc.
6 Previous Clinical Trials
349 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~7 spots leftby Mar 2025